Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil

被引：0
|
作者：
Martinez-Balibrea, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Abad, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Valladares, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Villacampa, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Aranda, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Marcuello, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Benavides, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Cardus, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Gines, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Manzano, J. L. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[2] Hosp Juan Canalejo, La Coruna, Spain
[3] Hosp Duran & Reynals, ICO, Lhospitalet De Llobregat, Spain
[4] Hosp Reina Sofia, Cordoba, Spain
[5] Hosp Sant Pau, Barcelona, Spain
[6] Hosp Carlos Haya, Malaga, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4066
引用
收藏
页数：2
相关论文
共 50 条
  • [21] 5-Fluorouracil/Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) as First-Line Treatment of Advanced Gastric Cancer
    Grande, C.
    Martinez, M.
    Villanueva, M. J.
    Huidobro, G.
    Casal, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S469 - S469
  • [22] The comprehensive analysis of UGT1A genetic polymorphisms in patients with metastatic gastrointestinal cancer treated with irinotecan chemotherapy
    Tsujinaka, T.
    Satoh, T.
    Ura, T.
    Sasaki, Y.
    Yamazaki, K.
    Munakata, M.
    Yamada, Y.
    Ishizuka, N.
    Hyodo, I.
    Sakata, Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 144 - 144
  • [23] The contribution of UGT1A and ABCB1 to irinotecan-induced toxicity: A prospective pharmacogenetic study of patients with metastatic colorectal cancer
    Levesque, E.
    Belanger, A.
    Couture, F.
    Jonker, D. J.
    Villeneuve, L.
    Harvey, M.
    Guillemette, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Pharmacogenetic approach for capecitabine or 5-fluorouracil (5FU) selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
    Martinez-Balibrea, E.
    Abad, A.
    Aranda, E.
    Sastre, J.
    Manzano, J. L.
    Aparicio, J.
    Garca, T.
    Maestu, I.
    Martinez-Cardus, A.
    Gines, A.
    Guino, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
    Carlini, LE
    Meropol, NJ
    Bever, J
    Andria, ML
    Hill, T
    Gold, P
    Rogatko, A
    Wang, H
    Blanchard, RL
    CLINICAL CANCER RESEARCH, 2005, 11 (03) : 1226 - 1236
  • [26] Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil
    Van Cutsem, E
    Blijham, GH
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 13 - 20
  • [27] Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
    A Ruzzo
    F Graziano
    F Loupakis
    D Santini
    V Catalano
    R Bisonni
    R Ficarelli
    A Fontana
    F Andreoni
    A Falcone
    E Canestrari
    G Tonini
    D Mari
    P Lippe
    F Pizzagalli
    G Schiavon
    P Alessandroni
    L Giustini
    P Maltese
    E Testa
    E T Menichetti
    M Magnani
    The Pharmacogenomics Journal, 2008, 8 : 278 - 288
  • [28] Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
    Ruzzo, A.
    Graziano, F.
    Loupakis, F.
    Santini, D.
    Catalano, V.
    Bisonni, R.
    Ficarelli, R.
    Fontana, A.
    Andreoni, F.
    Falcone, A.
    Canestrari, E.
    Tonini, G.
    Mari, D.
    Lippe, P.
    Pizzagalli, F.
    Schiavon, G.
    Alessandroni, P.
    Giustini, L.
    Maltese, P.
    Testa, E.
    Menichetti, E. T.
    Magnani, M.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (04): : 278 - 288
  • [29] Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer
    Rocha, Jose Aurillo
    ANTI-CANCER DRUGS, 2011, 22 : S9 - S13
  • [30] A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer
    Pan, CX
    Loehrer, P
    Seitz, D
    Helft, P
    Juliar, B
    Ansari, R
    Pletcher, W
    Vinson, J
    Cheng, L
    Sweeney, C
    ONCOLOGY, 2005, 69 (01) : 63 - 70
12345